Thomas J. Hwang

3.3k total citations
94 papers, 2.1k citations indexed

About

Thomas J. Hwang is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Thomas J. Hwang has authored 94 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Economics and Econometrics, 19 papers in Pediatrics, Perinatology and Child Health and 15 papers in Pharmacology. Recurrent topics in Thomas J. Hwang's work include Pharmaceutical Economics and Policy (57 papers), Health Systems, Economic Evaluations, Quality of Life (54 papers) and Economic and Financial Impacts of Cancer (22 papers). Thomas J. Hwang is often cited by papers focused on Pharmaceutical Economics and Policy (57 papers), Health Systems, Economic Evaluations, Quality of Life (54 papers) and Economic and Financial Impacts of Cancer (22 papers). Thomas J. Hwang collaborates with scholars based in United States, Switzerland and Spain. Thomas J. Hwang's co-authors include Aaron S. Kesselheim, Jessica M. Franklin, Kerstin Noëlle Vokinger, Florence T. Bourgeois, Julie C. Lauffenburger, Bishal Gyawali, Daniel Carpenter, Bo Wang, Ariadna Tibau and Jonathan J. Darrow and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.

In The Last Decade

Thomas J. Hwang

90 papers receiving 2.1k citations

Peers

Countries citing papers authored by Thomas J. Hwang

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Hwang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Hwang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Hwang more than expected).

Fields of papers citing papers by Thomas J. Hwang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Hwang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Hwang. The network helps show where Thomas J. Hwang may publish in the future.

Co-authorship network of co-authors of Thomas J. Hwang

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Hwang. A scholar is included among the top collaborators of Thomas J. Hwang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Hwang. Thomas J. Hwang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021 2023 ·JAMA Network Open ·Neeraj G. Patel, Thomas J. Hwang, Steven Woloshin, Aaron S. Kesselheim	6
2	Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019 2023 ·JAMA Health Forum ·Lisa Clemans-Cope, (unknown), Jessica S. Banthin, Aaron S. Kesselheim, Thomas J. Hwang	4
3	Mergers that Matter: The Impact of M&A Activity in Prescription Drug Markets 2023 ·SSRN Electronic Journal ·(unknown), Thomas J. Hwang, (unknown), (unknown)	1
4	Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study 2023 ·BMJ ·Kerstin Noëlle Vokinger, (unknown), Aaron S. Kesselheim, Miquel Serra‐Burriel, Joseph S. Ross, Thomas J. Hwang	17
5	Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis 2020 ·The Lancet Oncology ·Kerstin Noëlle Vokinger, Thomas J. Hwang, Thomas Grischott, Sophie Reichert, Ariadna Tibau, Thomas Rosemann, Aaron S. Kesselheim	130
6	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis 2018 ·JMIR Public Health and Surveillance ·Michael S. Sinha, Clark C. Freifeld, John S. Brownstein, Macarius Donneyong, (unknown), (unknown), Esther H. Zhou, Gerald J. Dal Pan, Ajinkya Pawar, Thomas J. Hwang, Jerry Avorn, Aaron S. Kesselheim	20
7	Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe 2018 ·Annals of Oncology ·Thomas J. Hwang, Kerstin Noëlle Vokinger, Ariadna Tibau, Bishal Gyawali, Huseyin Naci, (unknown), Reed F. Beall, Aaron S. Kesselheim	1
8	Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study 2018 ·PLoS Medicine ·Thomas J. Hwang, P. Tomasi, Florence T. Bourgeois	34
9	Expansion of the Priority Review Voucher Program Under the 21^st Century Cures Act: Implications for Innovation and Public Health 2018 ·American Journal of Law & Medicine ·Michael S. Sinha, Nina Jain, Thomas J. Hwang, Aaron S. Kesselheim	1
10	Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections 2016 ·American Journal of Law & Medicine ·Thomas J. Hwang, Aaron S. Kesselheim	4
11	Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study 2016 ·BMJ ·Thomas J. Hwang, (unknown), Jessica M. Franklin, Aaron S. Kesselheim	59
12	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012 2016 ·JACC Basic to Translational Science ·Thomas J. Hwang, Julie C. Lauffenburger, Jessica M. Franklin, Aaron S. Kesselheim	25
13	Two decades of new drug development for central nervous system disorders 2015 ·Nature Reviews Drug Discovery ·Aaron S. Kesselheim, Thomas J. Hwang, Jessica M. Franklin	114
14	Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002–2012 2015 ·BMJ Open ·(unknown), Thomas J. Hwang, Joseph B. Ciolino	13
15	Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies 2014 ·BMJ Open ·Thomas J. Hwang, (unknown), (unknown), Karin Weyer, Dennis Falzon, (unknown), Paul Nunn, Ernesto Jaramillo, Salmaan Keshavjee, D. F. Wares	57
16	Assessment of US pathway for approving medical devices for rare conditions 2014 ·BMJ ·Thomas J. Hwang, Daniel Carpenter, Aaron S. Kesselheim	11
17	Life Cycle of Medical Product Rules Issued by the US Food and Drug Administration 2014 ·Journal of Health Politics Policy and Law ·Thomas J. Hwang, Jerry Avorn, Aaron S. Kesselheim	7
18	Survey of MD/MBA Programs 2014 ·Academic Medicine ·(unknown), (unknown), Brian Oh, Thomas J. Hwang, (unknown), Sachin Jain	14
19	Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies 2013 ·PLoS ONE ·Thomas J. Hwang	22
20	Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis [Review article] 2013 ·The International Journal of Tuberculosis and Lung Disease ·Thomas J. Hwang, D. F. Wares, (unknown), Wieslaw Jakubowiak, P Nunn, Salmaan Keshavjee	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact